1. Home
  2. PRPO vs PSTV Comparison

PRPO vs PSTV Comparison

Compare PRPO & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • PSTV
  • Stock Information
  • Founded
  • PRPO N/A
  • PSTV 1996
  • Country
  • PRPO United States
  • PSTV United States
  • Employees
  • PRPO N/A
  • PSTV N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • PSTV Medical/Dental Instruments
  • Sector
  • PRPO Industrials
  • PSTV Health Care
  • Exchange
  • PRPO Nasdaq
  • PSTV Nasdaq
  • Market Cap
  • PRPO N/A
  • PSTV 10.4M
  • IPO Year
  • PRPO N/A
  • PSTV N/A
  • Fundamental
  • Price
  • PRPO $11.79
  • PSTV $0.30
  • Analyst Decision
  • PRPO
  • PSTV Strong Buy
  • Analyst Count
  • PRPO 0
  • PSTV 3
  • Target Price
  • PRPO N/A
  • PSTV $10.83
  • AVG Volume (30 Days)
  • PRPO 9.8K
  • PSTV 59.6M
  • Earning Date
  • PRPO 08-12-2025
  • PSTV 08-13-2025
  • Dividend Yield
  • PRPO N/A
  • PSTV N/A
  • EPS Growth
  • PRPO N/A
  • PSTV N/A
  • EPS
  • PRPO N/A
  • PSTV N/A
  • Revenue
  • PRPO $20,029,000.00
  • PSTV $5,206,000.00
  • Revenue This Year
  • PRPO N/A
  • PSTV $13.26
  • Revenue Next Year
  • PRPO N/A
  • PSTV $8.84
  • P/E Ratio
  • PRPO N/A
  • PSTV N/A
  • Revenue Growth
  • PRPO 26.67
  • PSTV N/A
  • 52 Week Low
  • PRPO $3.90
  • PSTV $0.16
  • 52 Week High
  • PRPO $12.45
  • PSTV $2.31
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 65.45
  • PSTV 45.82
  • Support Level
  • PRPO $10.60
  • PSTV $0.30
  • Resistance Level
  • PRPO $11.70
  • PSTV $0.37
  • Average True Range (ATR)
  • PRPO 0.60
  • PSTV 0.05
  • MACD
  • PRPO -0.08
  • PSTV 0.02
  • Stochastic Oscillator
  • PRPO 79.57
  • PSTV 50.00

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: